Skip to content

J Affect Disord

ISSN 0165-0327; 1573-2517;

21 papers in the library · 143 citations · publishing 2009-2026

Papers

Sort Most recent Most cited

Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).

J Affect Disord May 16, 2026 David S. Mathai, Madeleine Cluck, Amna M. Aslam et al. 1 citation

Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).

DOI: 10.1016/j.jad.2026.121970 (opens in new tab)

Changes in depression symptom network structure following ketamine treatment in treatment-resistant depression.

J Affect Disord May 14, 2026 Joshua Curtiss, Laya Dasari, Julianne Origlio et al.

Major Depressive Disorder (MDD) affects millions globally, with approximately 30% of patients experiencing treatment-resistant depression (TRD). While ketamine has emerged as a rapid-acting intervention, response rates remain variable, underscoring the need to refine precision medicine approaches for ketamine treatment. Network theories of mental health disorders have been promoted as framework...

DOI: 10.1016/j.jad.2026.121964 (opens in new tab)

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

J Affect Disord October 10, 2025 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. correction

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

DOI: 10.1016/j.jad.2025.120352 (opens in new tab) Psilocybin Treatment-resistant depression Psychedelic experience Unique experience +7

Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity.

J Affect Disord February 27, 2024 Debora Copa, David Erritzøe, Bruna Giribaldi et al. 31 citations

BackgroundPsilocybin is a serotonergic psychedelic drug under assessment as a potential therapy for treatment-resistant and major depression. Heterogeneous treatment responses raise interest in predicting the outcome from baseline data.MethodsA machine learning pipeline was implemented to investigate baseline resting-state functional connectivity measured with functional magnetic resonance...

DOI: 10.1016/j.jad.2024.02.089 (opens in new tab) Psychedelic therapy Psychedelic-assisted therapy Psilocybin therapy Psilocybin treatment +16

Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms.

J Affect Disord December 27, 2022 Aki Nikolaidis, Rafaelle Lancelotta, Natalie Gukasyan et al. 24 citations

BackgroundSubjective experiences seem to play an important role in the enduring effects of psychedelic experiences. Although the importance of the subjective experience on the impact of psychedelics is frequently discussed, a more detailed understanding of the subtypes of psychedelic experiences and their associated impacts on mental health has not been well documented.MethodsIn the current...

DOI: 10.1016/j.jad.2022.12.042 (opens in new tab) Full text (opens in new tab) Psychedelic-assisted therapy Psychedelic experiences Psychedelic journeys Hallucinogenic experiences +20

Virtual mindfulness interventions to promote well-being in adults: A mixed-methods systematic review.

J Affect Disord January 4, 2022 Joy Xu, Helen Jo, Leena Noorbhai et al. 30 citations

BackgroundWith the onset of the COVID-19 pandemic, many have experienced drastic changes in their academic and social lives with ensuing consequences towards their physical and mental well-being. The purpose of this systematic review is to identify virtual mindfulness-based interventions for the well-being of adults aged 19 to 40 years in developed countries and examine the efficacy of these...

DOI: 10.1016/j.jad.2022.01.027 (opens in new tab) Full text (opens in new tab) Digital mindfulness. Mental health. Stress reduction. Research review.

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.

J Affect Disord April 1, 2018 Facundo Carrillo, Mariano Sigman, Diego Fernández Slezak et al. 57 citations

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.

DOI: 10.1016/j.jad.2018.01.006 (opens in new tab) Psychedelic therapy Psilocybin therapy Psilocybin treatment Depression treatment +17